Clinical impact of early progression among patients (Pts) with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs) in first-line (1L) setting: IMPACT RCC real-world study.

被引：0
|
作者：
Hutson, Thomas E.
Liu, Frank Xiaoqing
Pandya, Shivani
Dieyi, Christopher
Kim, Ruth
Krulewicz, Stan
Kasturi, Vijay
Bhanegaonkar, Abhijeet
机构：
[1] Texas Oncol Sammons Canc Ctr, Dallas, TX USA
[2] EMD Serono Res & Dev Inst Inc, Rockland, MA USA
[3] STATinMED Res, Plano, TX USA
[4] Pfizer Inc, New York, NY USA
[5] Pfizer Inc, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e17079
引用
收藏
页数：2
相关论文
共 50 条
  • [1] IMPACT RCC REAL-WORLD STUDY: ECONOMIC IMPACT OF EARLY PROGRESSION AMONG PATIENTS WITH METASTATIC RENAL CELL CARCINOMA TREATED WITH TYROSINE KINASE INHIBITORS IN FIRST-LINE SETTING
    Bhanegaonkar, A.
    Pandya, S.
    Kim, R.
    Zheng, Y.
    Dieyi, C.
    Krulewicz, S.
    Kasturi, V
    Liu, F. X.
    Hutson, T. E.
    [J]. VALUE IN HEALTH, 2020, 23 : S42 - S43
  • [2] Real-world assessment of changing treatment patterns and sequence for patients with metastatic renal cell carcinoma (mRCC) in the first-line (1L) setting.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John A.
    McGregor, Bradley Alexander
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka N.
    Hansen, Aaron Richard
    Iafolla, Marco Adelmo James
    Zanotti, Giovanni
    Huynh, Lynn
    Duh, Mei Sheng
    Heng, Daniel Yick Chin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] Real-world clinical outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) in current immune-oncology (IO) and tyrosine kinase inhibitors (TKIs) era.
    Shah, Neil J.
    Sura, Sneha
    Shinde, Reshma
    Shi, Junxin
    Perini, Rodolfo F.
    Puneet, Singhal
    Robert, Nicholas J.
    Vogelzang, Nicholas J.
    Motzer, Robert J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis
    Hutson, Thomas E.
    Liu, Frank X.
    Dieyi, Christopher
    Kim, Ruth
    Krulewicz, Stan
    Kasturi, Vijay
    Bhanegaonkar, Abhijeet
    Care, J. Manag
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2021, 27 (09): : 1171 - 1181
  • [6] Prediction of early progression of metastatic renal cell carcinoma treated with first-line tyrosine kinase inhibitor
    Teishima, Jun
    Murata, Daiki
    Inoue, Shogo
    Hayashi, Tetsutaro
    Mita, Koji
    Hasegawa, Yasuhisa
    Kato, Masao
    Kajiwara, Mitsuru
    Shigeta, Masanobu
    Maruyama, Satoshi
    Moriyama, Hiroyuki
    Fujiwara, Seiji
    Matsubara, Akio
    [J]. CURRENT UROLOGY, 2021, 15 (04) : 187 - 192
  • [7] Real-world (RW) outcomes in metastatic renal cell carcinoma (mRCC) patients treated with first-line (1L) nivolumab plus ipilimumab (NIVO plus IPI) in the United States
    Geynisman, D.
    Chan, P.
    Robert, N.
    Chen, L.
    Del Tejo, V.
    Rosenblatt, L. C.
    Huo, S.
    Doshi, G.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1216 - S1216
  • [8] Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
    Dong, P.
    Huang, T.
    Jiang, L.
    Wei, W.
    Zheng, X.
    Zhang, Z.
    Guo, S.
    Han, H.
    Zhou, F.
    [J]. ANNALS OF ONCOLOGY, 2023, 34 : S1560 - S1561
  • [9] Real-world assessment of clinical outcomes among first-line (1 L) Sunitinib patients with metastatic renal cell carcinoma (MRCC) by the international Mrcc database consortium (IMDC) risk group
    Lynn Huynh
    Savard, Marie-France
    Wells, J. Connor
    Graham, Jeffrey
    Steinharter, John
    McGregor, Bradley
    Donskov, Frede
    Bjarnason, Georg A.
    Vaishampayan, Ulka
    Hansen, Aaron
    Iafolla, Marco
    Zanotti, Giovanni
    Nguyen, Catherine
    Chang, Rose
    Duh, Mei S.
    Heng, Daniel Y. C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 124 - 125
  • [10] Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.
    Heng, Daniel Yick Chin
    Doshi, Gury K.
    Dutailly, Pascale
    Houchard, Aude
    Lothgren, Mickael
    Monnette, Alisha
    Wang, Yunfei
    Perrot, Valerie
    Lalani, Aly-Khan A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345